Mass spectrometry-based multiplexing for the analysis of biomarkers in drug development and clinical diagnostics - How much is too much?

Microchemical Journal

Volumn 105, Issue , 2012, Pages 32-38

  Christians, Uwe ^a   Klepacki, Jacek ^a   Shokati, Touraj ^a   Klawitter, Jost ^a   Klawitter, Jelena ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Liquid chromatography mass spectrometry; Metabolomics; Multiplexing; Regulatory aspects; Validation

Indexed keywords

EID: 84867893625     PISSN: 0026265X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.microc.2012.02.011     Document Type: Article

References (31)

1. Oresic M., Vidal-Puig A., Hänninen V. Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev. Mol. Diagn. 2006, 6:575-585.
2. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarkers Definition Working Group.
3. Nobeli I., Thornton J.M. A bioinformatician's view of the metabolome. Bioessays 2006, 28:534-545.
4. Christians U., Klawitter J., Hornberger A., Klawitter J. How unbiased is non-targeted metabolomics and is targeted pathway screening the solution?. Curr. Pharm. Biotechnol. 2011, 12:1053-1066.
5. U.S.Department of Health and Human Services, Food and Drug Administration Challenge and opportunity on the critical path to new medical products (accessed 11/4/2011). http://www.nipte.org/docs/Critical_Path.pdf.
6. Müller P.Y., Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin. Drug Metab. Toxicol. 2009, 5:1023-1038.
7. United States Food and Drug Administration, Center for Drug Evaluation and Research Guidance for the Industry. Pharmacogenomic data submissions (accessed 11-4-2011). http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf.
8. Goodsaid F., Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007, 23:E105-E108.
9. Goodsaid F., Frueh F. Implementing the US FDA guidance on pharmacogenomic data submissions. Environ. Mol. Mutagen. 2007, 48:354-358.
10. Goodsaid F., Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006, 7:773-782.
11. Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 2007, 81:104-107.
12. Lee J.W., Figeys D., Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv. Cancer Res. 2007, 96:269-298.
13. Burckart G.J., Amur S., Goodsaid F.M., Lesko L.J., Frueh F.W., Huang S.M., Cavaille-Coll M.W. Qualification of biomarkers for drug development in organ transplantation. Am. J. Transplant. 2008, 8:267-270.
14. Lee J.W., Weiner R.S., Sailstad J.M., Bowsher R.R., Knuth D.W., O'Brien P.J., Fourcroy J.L., Dixit R., Pandite L., Pietrusko R.G., Soares H.D., Quarmby V., Vesterqvist O.L., Potter D.M., Witliff J.L., Fritche H.A., O'Leary T., Perlee L., Kadam S., Wagner J.A. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 2005, 22:499-511.
15. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products Version, (accessed 11-4-2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf.
16. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24:971-983.
17. Code Federal Regulations, Title 21, Food and drugs chapter i- -Food and Drug Administration, Department of Health and Human Services. Subchapter h, Medical Devices. Part 807, Establishment registration and device listing for manufacturers and initial importers of devices. (accessed 11-4-2011). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=807.
18. Code Federal Regulations, Title 21, Food and drugs chapter i- -Food and Drug Administration, Department of Health and Human Services. Subchapter h, Medical Devices. Part 814, Premarket approval of medical devices. (accessed 11-4-2011). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=814.
19. Ministerial ordinance on standards for manufacturing control and quality control for medical devices and in-vitro diagnostic reagents. (Pharmaceuticals and Medical Devices Agency, Tokyo) (accessed 11-4-2011). http://meddevmirq.com/Documents/MiRQ%20Overview%20of%20Japanese%20Regulatory%20System_PAL%20Summary%202009_07_18%20Sec%202.pdf.
20. Dati F. The new European directive on in vitro diagnostics. Clin. Chem. Lab. Med. 2003, 41:1289-1298.
21. Annesley T.M. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49:1041-1044.
22. Klawitter J., Schmitz V., Klawitter J., Leibfritz D., Christians U. Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal. Biochem. 2007, 365:230-239.
23. Wickremsinhe E.R., Ackermann B.L., Chaudhary A.K. Validating regulatory-compliant wide dynamic range bioanalytical assays using chip-based nanoelectrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:47-56.
24. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine Guidance for the Industry. Bioanalytical Method Validation Version, (accessed 11-4-2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
25. Clinical Laboratory and Standard Institute (accessed 11-4-2011). http://www.clsi.org.
26. European Agency for the Evaluation of Medicinal Products ICH topic Q2 (R1). Validation of analytical procedures: text and methodology. Note for guidance on analytical procedures: Text and methodology. CPMP ICH/381/95 (accessed 11-4-2011). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf.
27. Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008, 153:646-656.
28. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Version, (assessed 11-4-2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
29. 2t-isoprostane in human urine and plasma using high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Clin. Chem. 2007, 53:489-497.
30. Klawitter M., Haschke T., Shokat J., Klawitter U. Christians, quantification of 15-F2t-isoprostane in human plasma and urine: ELISA and LC-MS/MS results cannot be compared. Rapid Commun. Mass Spectrom. 2011, 25:463-468.
31. Goodsaid F.M., Frueh F.W., Mattes W. Strategic paths for biomarker qualification. Toxicology 2008, 245:219-223.